You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What information is available regarding alcohol use with Zepbound® (tirzepatide)?
Eli Lilly and Company has not evaluated tirzepatide for alcohol use disorder or with concomitant alcohol use.
See important safety information, including boxed warning, in the attached prescribing information.
Alcohol Use
Eli Lilly and Company cannot provide a recommendation on whether to use tirzepatide in a patient with concomitant alcohol use or comorbid alcohol use disorder (AUD). The healthcare practitioner may use the information provided, the patient’s prior medical history and concomitant medications, and other individual factors in developing a treatment plan. The healthcare practitioner should consider potential risks and benefits of treatment options and monitor appropriately.
Lilly cannot provide any information on tirzepatide and concomitant alcoholic beverage use because this has not been studied by Lilly.
In tirzepatide clinical trials conducted by Lilly, patients were excluded if they had a history of alcohol abuse or any condition that, in the opinion of the investigator, may preclude the patient from following and completing the protocol.1
Tirzepatide is not indicated for AUD.2
Although some independent, non-Lilly, studies on the use of tirzepatide in AUD exist, Lilly
has not sponsored or reviewed these studies
is not affiliated with these studies
cannot confirm their scientific merit, clinical relevance, or generalizability, and
Enclosed Prescribing Information
ZEPBOUND® (tirzepatide) injection, for subcutaneous use, Lilly
1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2. Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: December 03, 2025